| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
From the Neurological Institute, Columbia-Presbyterian Medical Center, New York, NY.
Presented in part in abstract form at the 47th annual meeting of the American Academy of Neurology, Seattle, WA, May 1995.
Received October 31, 1995. Accepted in final form March 22, 1996.
Address correspondence and reprint requests to Dr. Thomas Brannagan, Neurological Institute Unit 96, 710 W 168th Street, New York, NY 10032.
Intravenous immune globulin (IVIg) is advocated as a safe treatment for immune-mediated neurologic disease. We reviewed the medical records of 88 patients who were given IVIg for a neurologic illness. Major complications in four patients (4.5%) included congestive heart failure in a patient with polymyositis, hypotension after a recent myocardial infarction, deep venous thrombosis in a bed-bound patient, and acute renal failure with diabetic nephropathy. Other adverse effects included vasomotor symptoms 26, headache 23, rash 5, leukopenia 4, fever 3, neutropenia 1, proteinuria (1.9 g/day) 1, viral syndrome 1, dyspnea 1, and pruritis 1. Fifty-two patients (59%) had some adverse effect of IVIg infusion, most commonly vasomotor symptoms, headaches, fever, or shortness of breath in 40 (45%), which improved with reduced infusion rate or symptomatic medications. Five (6%) had asymptomatic laboratory abnormalities and seven (8%) had other minor adverse effects. Adverse effects led to discontinuation of therapy in 16% and permanent termination of therapy in 10% of patients. There was no mortality or long-term morbidity. Although adverse effects were frequent, serious complications were rare except in patients with heart disease, renal insufficiency, and bed-bound state.
NEUROLOGY 1996;47: 674-677
This article has been cited by other articles:
|
|
 |
|
  Y A Rajabally Multifocal motor neuropathy: review of a treatable immune mediated disorder Postgrad. Med. J., June 1, 2008; 84(992): 287 - 292. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. R. Kayyali, A. T. Abdelmoity, M. C. Morriss, and W. D. Graf Cerebral Venous Thrombosis After Immune Thrombocytopenic Purpura and Anti-D Immune Globulin Therapy J Child Neurol, March 1, 2008; 23(3): 325 - 330. [Abstract] [PDF]
|
|
|
|
 |
|
 X. J. Caro, E. F. Winter, and A. J. Dumas A subset of fibromyalgia patients have findings suggestive of chronic inflammatory demyelinating polyneuropathy and appear to respond to IVIg Rheumatology, February 1, 2008; 47(2): 208 - 211. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. M Gurcan and A R. Ahmed Frequency of Adverse Events Associated with Intravenous Immunoglobulin Therapy in Patients with Pemphigus or Pemphigoid Ann. Pharmacother., October 1, 2007; 41(10): 1604 - 1610. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Jarius, P. Eichhorn, M. H. Albert, S. Wagenpfeil, M. Wick, B. H. Belohradsky, R. Hohlfeld, D. E. Jenne, and R. Voltz Intravenous immunoglobulins contain naturally occurring antibodies that mimic antineutrophil cytoplasmic antibodies and activate neutrophils in a TNF{alpha}-dependent and Fc-receptor-independent way Blood, May 15, 2007; 109(10): 4376 - 4382. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. M Gurcan and A R. Ahmed Efficacy of Various Intravenous Immunoglobulin Therapy Protocols in Autoimmune and Chronic Inflammatory Disorders Ann. Pharmacother., May 1, 2007; 41(5): 812 - 823. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 U Katz and Y Shoenfeld Review: intravenous immunoglobulin therapy and thromboembolic complications Lupus, October 1, 2005; 14(10): 802 - 808. [Abstract] [PDF]
|
|
|
|
 |
|
 S. Vucic, K. R. Black, P. S. T. Chong, and D. Cros Multifocal motor neuropathy: Decrease in conduction blocks and reinnervation with long-term IVIg Neurology, October 12, 2004; 63(7): 1264 - 1269. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. B. Caress, M. S. Cartwright, P. D. Donofrio, and J. E. Peacock Jr. The clinical features of 16 cases of stroke associated with administration of IVIg Neurology, June 10, 2003; 60(11): 1822 - 1824. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N Evangelou, T Littlewood, P Anslow, and H Chapel Transverse sinus thrombosis and IVIg treatment: a case report and discussion of risk-benefit assessment for immunoglobulin treatment J. Clin. Pathol., April 1, 2003; 56(4): 308 - 309. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. H. Brannagan III Intravenous gammaglobulin (IVIg) for treatment of CIDP and related immune-mediated neuropathies Neurology, December 24, 2002; 59(90126): S33 - 40. [Abstract] [Full Text]
|
|
|
|
|
|
N. P. Byrne, J. C. Henry, D. N. Herrmann, A. N. Abdelhalim, D. A. Shrier, C. W. Francis, and J. M. Powers Neuropathologic findings in a Guillain-Barre patient with strokes after IVIg therapy Neurology, August 13, 2002; 59(3): 458 - 461. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C M Wiles, P Brown, H Chapel, R Guerrini, R A C Hughes, T D Martin, P McCrone, J Newsom-Davis, J Palace, J H Rees, et al. Intravenous immunoglobulin in neurological disease: a specialist review J. Neurol. Neurosurg. Psychiatry, April 1, 2002; 72(4): 440 - 448. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. A. Grillo, K. C. Gorson, A. H. Ropper, J. Lewis, and R. Weinstein Rapid infusion of intravenous immune globulin in patients with neuromuscular disorders Neurology, November 13, 2001; 57(9): 1699 - 1701. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J-C Raphael, S Chevret, M Harboun, and M-C. Jars-Guincestre Intravenous immune globulins in patients with Guillain-Barre syndrome and contraindications to plasma exchange: 3 days versus 6 days J. Neurol. Neurosurg. Psychiatry, August 1, 2001; 71(2): 235 - 238. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C Alliot, J P Rapin, M Besson, F Bedjaoui, and D Messouak Pulmonary embolism after intravenous immunoglobulin J R Soc Med, April 1, 2001; 94(4): 187 - 188. [Full Text] [PDF]
|
|
|
|
 |
|
 J.B. Levy and C.D. Pusey Nephrotoxicity of intravenous immunoglobulin QJM, November 1, 2000; 93(11): 751 - 755. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 O. Elkayam, D. Paran, R. Milo, Y. Davidovitz, D. Almoznino-Sarafian, D. Zeltser, M. Yaron, and D. Caspi Acute myocardial infarction associated with high dose intravenous immunoglobulin infusion for autoimmune disorders. A study of four cases Ann Rheum Dis, January 1, 2000; 59(1): 77 - 77. [Abstract] [Full Text]
|
|
|
|
 |
|
 P. S. Sorensen Intravenous Immunoglobulin Treatment in Neurologic Disorders: Yes Arch Neurol, August 1, 1999; 56(8): 1025 - 1027. [Full Text] [PDF]
|
|
|
|
 |
|
 J. Guy and N. Aptsiauri Treatment of Paraneoplastic Visual Loss With Intravenous Immunoglobulin: Report of 3 Cases Arch Ophthalmol, April 1, 1999; 117(4): 471 - 477. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M Howse, L Bindoff, A Carmichael, M D Thomas, and L J Cook Drug points: Facial vasculitic rash associated with intravenous immunoglobulin • Fever associated with cyclosporin for treating atopic dermatitis BMJ, November 7, 1998; 317(7168): 1291 - 1291. [Full Text]
|
|
|
|
|
|
F L Mastaglia, B A Phillips, and P J Zilko Immunoglobulin therapy in inflammatory myopathies J. Neurol. Neurosurg. Psychiatry, July 1, 1998; 65(1): 107 - 110. [Abstract] [Full Text]
|
|
|
|
|
|
B. L. Y. Wong and T. A. Glauser Single High-Dose Intravenous Immunoglobulin for Treatment of Pediatric Guillain-Barre Syndrome J Child Neurol, March 1, 1998; 13(3): 146 - 146. [PDF]
|
|
|
|
|
|
S. A. Abd-Allah, P. W. Jansen, S. Ashwal, and R. M. Perkin Intravenous Immunoglobulin as Therapy for Pediatric Guillain-Barre Syndrome J Child Neurol, September 1, 1997; 12(6): 376 - 380. [Abstract] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
